This study will investigate the use of a new medicine called sacituzumab govitecan (Trodelvy®)  when compared to standard of care chemotherapy. 

Trial Status
Trial Phase
Phase 3 Drug Trial
Registry Listing
ERM Project ID
Trial contact details
Contact Person
Donna Harvey
What you need to know

Who can take part?

Patients with previously untreated advanced triple-negative breast cancer (TNBC).

What is involved for you?

Half of all patients enrolled in this trial will receive the investigational product, and half will receive the doctors choice of chemotherapy. All medicines will be administered via an IV infusion. Each visit to the clinic will be accompanied by review by the study doctor and nurse, as well as blood collection, ECG's and  physical assessments. Regular tumour assessments via scans will occur. Patients on the standard of care arm of the trial, may be given an opportunity to cross over to the experimental treatment if certain criteria are meet during the trial.

All research clinical trials news

When Monique Perry was diagnosed with aggressive triple-negative breast cancer she feared her family history was about to repeat itself.



Clinical trials give Queensland breast cancer patients hope

Mater researchers in Brisbane are leading a trial of a game-changing flu vaccine that has the potential to provide greater and more durable protection against the virus.



Mater launches trial of Australian-first flu vaccine

Stephanie Guilas has worked in many departments throughout Mater Hospital Brisbane, however, after 28 years of service, she found her true passion working within Mater Research’s Mothers and Babies...



Stephanie Guilas is improving outcomes for mums and bubs through research

Displaying results 1-3 (of 17)
 |<  < 1 - 2 - 3 - 4 - 5 - 6  >  >|